Sofamor Danek tissue resector
This article was originally published in The Gray Sheet
Executive SummaryDesigned to remove bulging or herniated discs "in a minimally invasive manner" will be launched this month, President and CEO Ron Pickard told investors at the recent Hambrecht & Quist life sciences conference in San Francisco. In addition, the firm's disc spacer is scheduled to enter European clinicals this year, with an investigational device exemption expected to be filed with FDA later in 1994. The firm also hopes to start European clinicals for its prosthetic disc late this year, with an IDE submission anticipated in 1995
You may also be interested in...
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”
CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.
Anticipating a July approval of its cantharidin formulation, Verrica says it is poised to implement a buy-and-bill model for a clinician-administered product with an addressable market of 6 million.